Sanofi $SNY Stock Acquired by Mondrian Investment Partners LTD

Mondrian Investment Partners LTD increased its position in Sanofi (NASDAQ:SNY) by 2.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,652,139 shares of the company’s stock after buying an additional 129,575 shares during the period. Sanofi accounts for 5.0% of Mondrian Investment Partners LTD’s portfolio, making the stock its 6th largest holding. Mondrian Investment Partners LTD owned 0.23% of Sanofi worth $233,038,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Kendall Capital Management bought a new position in Sanofi during the third quarter valued at approximately $202,000. Evergreen Capital Management LLC lifted its stake in Sanofi by 23.3% in the third quarter. Evergreen Capital Management LLC now owns 20,079 shares of the company’s stock valued at $828,000 after acquiring an additional 3,800 shares during the last quarter. Gibbs Wealth Management grew its position in Sanofi by 15.7% in the third quarter. Gibbs Wealth Management now owns 29,885 shares of the company’s stock worth $1,232,000 after acquiring an additional 4,052 shares in the last quarter. Root Financial Partners LLC bought a new stake in Sanofi in the third quarter worth approximately $27,000. Finally, Cardinal Capital Management increased its stake in shares of Sanofi by 7.5% during the 3rd quarter. Cardinal Capital Management now owns 86,444 shares of the company’s stock worth $3,564,000 after purchasing an additional 5,994 shares during the last quarter. Institutional investors and hedge funds own 14.03% of the company’s stock.

Sanofi Price Performance

Shares of SNY stock opened at $41.60 on Friday. The company has a current ratio of 0.99, a quick ratio of 0.64 and a debt-to-equity ratio of 0.21. The firm has a market capitalization of $100.86 billion, a price-to-earnings ratio of 21.78, a PEG ratio of 1.28 and a beta of 0.33. The firm’s 50 day moving average is $42.43 and its 200-day moving average is $43.56. Sanofi has a 1 year low of $39.07 and a 1 year high of $52.68.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, July 30th. The company reported $2.41 earnings per share for the quarter. The firm had revenue of $13.36 billion during the quarter. Sanofi had a net margin of 8.66% and a return on equity of 14.19%. The business’s revenue for the quarter was up 16.0% on a year-over-year basis. During the same quarter last year, the firm earned $3.24 EPS. Sell-side analysts forecast that Sanofi will post 5.00 EPS for the current fiscal year.

Analyst Ratings Changes

SNY has been the topic of a number of recent research reports. JPMorgan Chase & Co. restated a “neutral” rating on shares of Sanofi in a report on Thursday, October 1st. Morgan Stanley set a $49.00 target price on Sanofi in a report on Wednesday, July 8th. Jefferies Financial Group restated a “buy” rating on shares of Sanofi in a research note on Thursday, October 1st. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Sanofi in a research report on Tuesday, September 29th. Finally, Weiss Ratings raised Sanofi from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday, October 8th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Sanofi currently has an average rating of “Hold” and a consensus price target of $49.50.

About Sanofi

Sanofi is a France-based global healthcare company that researches, develops, manufactures and markets prescription medicines and vaccines. Its operations focus primarily on specialty medicines, immunology, rare diseases, neurology, oncology and treatments for rare blood disorders, as well as established pharmaceutical products.

The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron; vaccines for influenza, polio, meningitis and other infectious diseases; and treatments for conditions including multiple sclerosis, hemophilia and certain rare diseases.